Delivery Order SPE2DR25D9168-SPE2DR26FCRM2

The Defense Logistics Agency (DLA) awarded a $24,948.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EYLEA 2 mg/0.05 mL syringes. This delivery order, issued on December 3, 2025, with an ultimate completion date of December 24, 2025, contains no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was awarded on November 13, 2025.

The underlying PPV-G GEN V contract, valued at $499,999,999 with a completion date of December 31, 2036, represents DMS Pharmaceutical Group's appointment as a regional prime vendor contractor within a $30.3 billion DLA acquisition strategy to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities globally. The IDC authorizes the issuance of delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. DMS Pharmaceutical Group has demonstrated substantial federal contracting activity and maintains no identified subcontractor relationships, serving as a critical supplier within the military medical supply chain across multiple therapeutic categories.